Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
DARE Stock Forecast 2026-2027
$2.03
Current Price
$27.36M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DARE Price Targets
+491.1%
To High Target of $12.00
+466.5%
To Median Target of $11.50
+294.1%
To Low Target of $8.00
DARE Price Momentum
-1.9%
1 Week Change
-11.0%
1 Month Change
-39.0%
1 Year Change
+5.2%
Year-to-Date Change
-77.9%
From 52W High of $9.19
+26.1%
From 52W Low of $1.61
๐ TOP ANALYST CALLS
Did DARE Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Dare Bioscience is one of their latest high-conviction picks.
Latest DARE Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, DARE has a bullish consensus with a median price target of $11.50 (ranging from $8.00 to $12.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.03, the median forecast implies a 466.5% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 491.1% upside. Conversely, the most conservative target is provided by Caroline Palomeque at Maxim Group, suggesting a 294.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DARE Analyst Ratings
4
Buy
0
Hold
0
Sell
DARE Price Target Range
Low
$8.00
Average
$11.50
High
$12.00
Current: $2.03
Latest DARE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DARE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Sep 4, 2025 | Maxim Group | Caroline Palomeque | Buy | Upgrade | $8.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Dec 17, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Aug 16, 2024 | Jones Trading | Catherine Novack | Buy | Maintains | $13.00 |
| Aug 14, 2024 | Maxim Group | Caroline Palomeque | Hold | Downgrade | $N/A |
| May 15, 2024 | Brookline Capital | Kemp Dolliver | Buy | Upgrade | $3.00 |
| May 15, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $6.00 |
| May 1, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $6.00 |
| Apr 17, 2024 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $N/A |
| Apr 1, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $6.00 |
| Nov 10, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $6.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Jul 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 6, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| May 22, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| May 12, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Mar 31, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
Dare Bioscience Inc. (DARE) Competitors
The following stocks are similar to Dare Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DARE
Dare Bioscience
mkt cap
28.29M
Dare Bioscience Inc. (DARE) Financial Data
Dare Bioscience Inc. has a market capitalization of $27.36M with a P/E ratio of 0.1x. The company generates $-57,130 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -94.6% quarter-over-quarter, while maintaining an operating margin of -162,340.8% and return on equity of -2,543.1%.
Valuation Metrics
Market Cap
$27.36M
Enterprise Value
$7.44M
P/E Ratio
0.1x
PEG Ratio
0.0x
Price/Sales
-457.7x
Growth & Margins
Revenue Growth (YoY)
-94.6%
Gross Margin
+100.0%
Operating Margin
-162,340.8%
Net Margin
0.0%
EPS Growth
-94.6%
Financial Health
Cash/Price Ratio
+79.6%
Current Ratio
1.2x
Debt/Equity
102.6x
ROE
-2,543.1%
ROA
-44.7%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Dare Bioscience Inc. (DARE) Business Model
About Dare Bioscience Inc.
What They Do
Develops innovative products for women's reproductive health.
Business Model
Dare Bioscience Inc. operates as a clinical-stage biopharmaceutical company focusing on women's health. It generates revenue by developing and commercializing therapeutic products that address unmet needs in areas such as fertility, contraception, and vaginal health, through both hormonal and non-hormonal solutions.
Additional Information
The company emphasizes partnerships and research collaborations to foster innovation in women's health. Its strategic approach aims to create effective healthcare solutions that enhance the quality of life for women, thereby establishing its significance in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Ms. Sabrina Martucci Johnson
Country
United States
IPO Year
2014
Website
darebioscience.comDare Bioscience Inc. (DARE) Latest News & Analysis
Latest News
Quick Summary
DARE to PLAYโข Sildenafil Cream, a first female arousal cream, increases genital blood flow and arousal sensations. Its market launch aims to advance women's sexual health.
Why It Matters
The introduction of DARE to PLAYโข could disrupt the women's health market, potentially increasing sales for the company and attracting investor interest in innovative healthcare solutions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Darรฉ Bioscience, Inc. discussed its Sildenafil Cream, DARE to PLAY, as a treatment for female genital arousal concerns in a conference call on November 17, 2025.
Why It Matters
Darรฉ Bioscience's discussion on sildenafil cream for female arousal concerns could indicate potential market expansion and revenue growth, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Darรฉ Bioscience, Inc. will host its Q3 2025 earnings call on November 13, 2025, at 4:30 PM EST to discuss financial results and provide a business update.
Why It Matters
Darรฉ Bioscience's Q3 earnings call will provide insights into financial performance and strategic direction, influencing investor sentiment and potential valuation adjustments.
Source: Seeking Alpha
Market Sentiment:
Neutral
Darรฉ Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2 months ago
Quick Summary
DARE to PLAYโข Sildenafil Cream is set to launch by year-end. Positive interim results for Ovapreneยฎ support continued enrollment. Four new women's health solutions expected in two years.
Why It Matters
The imminent launch of Sildenafil Cream and positive trial results for Ovaprene signal potential revenue growth, while advancing programs indicate a strong pipeline, enhancing market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dare Bioscience, Inc. reported a quarterly loss of $0.28 per share, beating the Zacks Consensus Estimate of $0.33, and improved from a loss of $0.55 per share a year prior.
Why It Matters
Dare Bioscience's smaller-than-expected quarterly loss indicates improving financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Dareฬ Bioscience, Inc. (NASDAQ: DARE) will hold a conference call on November 13, 2025, at 4:30 PM ET to discuss Q3 2025 financial results and company updates.
Why It Matters
Dareฬ Bioscience's upcoming financial results and company update may indicate its performance and future direction, impacting investor sentiment and stock value in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DARE Stock
What is Dare Bioscience Inc.'s (DARE) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Dare Bioscience Inc. (DARE) has a median price target of $11.50. The highest price target is $12.00 and the lowest is $8.00.
Is DARE stock a good investment in 2026?
According to current analyst ratings, DARE has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DARE stock?
Wall Street analysts predict DARE stock could reach $11.50 in the next 12 months. This represents a 466.5% increase from the current price of $2.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dare Bioscience Inc.'s business model?
Dare Bioscience Inc. operates as a clinical-stage biopharmaceutical company focusing on women's health. It generates revenue by developing and commercializing therapeutic products that address unmet needs in areas such as fertility, contraception, and vaginal health, through both hormonal and non-hormonal solutions.
What is the highest forecasted price for DARE Dare Bioscience Inc.?
The highest price target for DARE is $12.00 from Douglas Tsao at HC Wainwright & Co., which represents a 491.1% increase from the current price of $2.03.
What is the lowest forecasted price for DARE Dare Bioscience Inc.?
The lowest price target for DARE is $8.00 from Caroline Palomeque at Maxim Group, which represents a 294.1% increase from the current price of $2.03.
What is the overall DARE consensus from analysts for Dare Bioscience Inc.?
The overall analyst consensus for DARE is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.50.
How accurate are DARE stock price projections?
Stock price projections, including those for Dare Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 8:41 AM UTC